Azixa verubulin: Phase II data

Data from a subset of 25 patients who failed first- and second-line therapy, including treatment with Avastin bevacizumab, in an ongoing, open-label, U.S. Phase II trial in 56 patients showed that once-weekly 3.3 mg/m 2 IV Azixa for 3 weeks of a 4-week cycle led to a mean OS of 105 days. Additionally, Azixa led to tumor regression of >80% in 1 patient, while 4 patients achieved stable disease. Azixa was well tolerated. Data were presented at the Society for Neuro-Oncology meeting in Montreal. ...